Parkman Healthcare Partners LLC Reduces Holdings in Amicus Therapeutics, Inc. $FOLD

Key Points

• Parkman Healthcare Partners LLC reduced its stake in Amicus Therapeutics by 27.5%, selling 215,424 shares during the first quarter.
• Amicus Therapeutics saw a stock price decline of 0.4%, opening at $7.99 with a market cap of $2.46 billion.
• Despite recent changes, analysts maintain a consensus rating of "Moderate Buy" for Amicus Therapeutics, with an average price target of $16.00.

Parkman Healthcare Partners LLC trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 27.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 568,952 shares of the biopharmaceutical company's stock after selling 215,424 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.18% of Amicus Therapeutics worth $4,643,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new stake in shares of Amicus Therapeutics in the fourth quarter valued at about $132,000. Northern Trust Corp lifted its position in Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after purchasing an additional 187,652 shares during the period. Jane Street Group LLC boosted its holdings in Amicus Therapeutics by 7.8% in the 4th quarter. Jane Street Group LLC now owns 324,270 shares of the biopharmaceutical company's stock valued at $3,055,000 after purchasing an additional 23,524 shares in the last quarter. Ameriprise Financial Inc. increased its position in Amicus Therapeutics by 4.2% during the 4th quarter. Ameriprise Financial Inc. now owns 403,127 shares of the biopharmaceutical company's stock worth $3,797,000 after purchasing an additional 16,179 shares during the period. Finally, Cetera Investment Advisers purchased a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $113,000.

Amicus Therapeutics Price Performance

FOLD stock traded up $0.08 during midday trading on Thursday, hitting $8.02. 1,906,051 shares of the stock were exchanged, compared to its average volume of 3,868,413. The stock's 50-day moving average price is $6.87 and its 200-day moving average price is $7.03. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of -66.83 and a beta of 0.55. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a report on Thursday, July 17th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.